BiotechTube
Home/Pipeline/KRAS G12D-Targeted PCC

KRAS G12D-Targeted PCC

Pancreatic Cancer

PreclinicalActive

Key Facts

Indication
Pancreatic Cancer
Phase
Preclinical
Status
Active
Company
Indi Molecular

About Indi Molecular

Indi Molecular is a private, preclinical-stage biotech leveraging its proprietary Protein Catalyzed Capture (PCC) platform to create synthetic peptide therapeutics with antibody-like binding properties. Founded in 2012 as a spinout from Integrated Diagnostics, the company has raised a $1.5M seed round and an $11.5M Series A to advance its platform and two lead oncology programs. Its approach aims to combine the high specificity of biologics with the favorable pharmacokinetics and manufacturability of small molecules.

View full company profile

Therapeutic Areas

Oncology

Other Pancreatic Cancer Drugs

DrugCompanyPhase
Ampligen® (rintatolimod)AIM ImmunoTechEarly Access Program
HBM9027Harbour BioMedPhase 1
Small-Molecule TherapeuticAIkido LabsPre-clinical
AHPBA IRE RegistryAngioDynamicsPost-Market Registry
SIMBs + ImmunotherapyAdvanced MicrobubblesPre-clinical
CLS-014CLS TherapeuticsPre-clinical
SOMA PlatformCoherence NeuroPre-clinical
NP-G2-044Novita PharmaceuticalsPhase 2a
Pritumumab (PTB)Nascent BiotechPhase II (Planned)
Pancreatic Cancer TestMosaique DiagnosticDevelopment
Iontophoretic SystemContinuity BiosciencesPre-clinical
Lixumistat (IM156)ImmunoMet TherapeuticsPhase 1b